Identifying the Right Investigators and Patients for your Study – Mini Podcast Biosimilar Development Capabilities – Watch Now Vaccine Development Capabilities - Brochure Check out our latest Validated PK & ADA Methods List Read about Veeda's partnership with Ahammune Biosciences for first in human studies Check out our Assay List (Method Library)

Webinars

Webinar on Bioanalytical Method Development and Validation for Respiratory Drugs

Webinar on Challenges & Considerations in Designing & Conducting Phase II Immuno Oncology Trial

Webinar on Comparative Clinical Endpoint and Pharmacodynamic Bioequivalence Studies

Webinar on Challenges and Solutions: Development and Validation of Omalizumab Clinical Assays

Webinar on Bioanalysis of New Chemical Entities NCEs and Case Studies

Webinar on Challenges & Solutions Development and Validation of Abatacept Biosimilar Clinical Assays

Webinar on Vitiligo: Treatment and Beyond

Webinar on Dermatology Study Design, Regulatory Strategies, and Patient Participation

Webinar on Phase I Studies for Oncology Products

Webinar on Data Safety Assessment in Clinical Trials

Webinar on Bioanalytical aspects of BA/ BE studies for Endogenous Molecule

The growing prominence of Tyrosine Kinase Inhibitors (TKIs) and its Bioequivalence Studies

Stereo-isomeric drugs and Bioanalysis

Long-Acting Injectable Antipsychotics

Regulatory & Pharmacovigilance Considerations for NCEs

India's Resurgence as a Clinical Trial Destination

Approaches used in Replicate Bioequivalence Studies

First in Man Studies – Strategies for a Successful Outcome.

Population Bioequivalence for In-Vitro Studies.

Podcasts

Mini-Podcast on First-in-Human Trial for Vitiligo

Podcast on Addressing Key Challenges of Conducting First Monoclonal Antibody (Omalizumab) Study

Mini-Podcast on Identifying the Right Investigators and Patients for your Study

Mini-Podcast on Bioanalytical Complex Assay Development

Request for Proposal

Submit your details and we’ll be in touch shortly. You can also email us if you would prefer.